文献速递生殖医学

既往生育史与囊胚整倍体率及整倍体移植活产率的关系

Leave the past behind: women's reproductive history shows no association with blastocysts' euploidy and limited association with live birth rates after euploid embryo transfers.
PubMed 文献 · Hum Reprod · 2021-01-01

该观察性研究纳入2676例PGT-A周期患者,分析既往生育史与平均整倍体率(m-ER)及首次单囊胚移植活产率的关系。结果显示m-ER仅与女方取卵年龄相关,与既往生育史无关;活产率在反复种植失败(RIF)患者中降低,尤其是>2次失败者。

要点

  • 既往生育史不影响囊胚平均整倍体率。
  • RIF>2次者整倍体囊胚移植活产率显著低于无失败史者。
  • 整倍体囊胚移植后活产率44%,流产率14%。

核心结论

  • 女方既往生育史与囊胚平均整倍体率无关。
  • 既往反复种植失败(RIF)史与整倍体囊胚移植后活产率降低相关,尤其>2次失败者。

研究设计与样本

  • 分析m-ER与既往活产、流产、IVF失败周期及种植失败次数的关系,并分析1580例首次单囊胚移植的临床结局。

主要发现

  • 取卵时女方年龄是唯一与m-ER显著相关的变量;各年龄组m-ER分别为<35岁66±31%、35-37岁58±33%、38-40岁43±35%、40-42岁28±34%、>42岁17±31%。
  • m-ER与既往活产数、流产数、IVF失败周期数或种植失败次数均无关联。
  • 首次单囊胚移植的种植率51%,流产率14%,活产率44%。
  • 活产率与既往流产次数无关,但随既往种植失败次数增加呈下降趋势;>2次失败者与无失败史者相比为36% vs 47%(P<0.01),校正胚胎质量和囊胚发育天数后OR 0.64(95%CI 0.48-0.86,P<0.01)。

临床怎么用

  • 咨询PGT-A患者时,可告知既往生育史不影响囊胚整倍体率。
  • 对既往RIF患者,尤其>2次失败者,应告知整倍体囊胚移植后活产率仍可能降低。

局限性

  • 既往完成PGT-A周期后再次治疗的患者样本量需扩大。
  • 数据需多中心验证。
  • 未纳入非PGT周期及未产生囊胚的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is there an association between patients' reproductive history and the mean euploidy rates per biopsied blastocysts (m-ER) or the live birth rates (LBRs) per first single vitrified-warmed euploid blastocyst transfers? SUMMARY ANSWER: Patients' reproductive history (as annotated during counselling) showed no association with the m-ER, but a lower LBR was reported after euploid blastocyst transfer in women with a history of repeated implantation failure (RIF). WHAT IS KNOWN ALREADY: Several studies have investigated the association between the m-ER and (i) patients' basal characteristics, (ii) ovarian stimulation strategy and dosage, (iii) culture media and conditions, and (iv) embryo morphology and day of full blastocyst development. Conversely, the expected m-ER due to women's reproductive history (previous live births (LBs), miscarriages, failed IVF cycles and transfers, and lack of euploid blastocysts among prior cohorts of biopsied embryos) still needs investigations. Yet, this information is critical to counsel new patients about a first cycle with preimplantation genetic testing for aneuploidy (PGT-A), but even more so after former adverse outcomes to prevent treatment drop-out. STUDY DESIGN, SIZE, DURATION: This observational study included all patients undergoing a comprehensive chromosome testing (CCT)-based PGT-A cycle with at least one biopsied blastocyst in the period April 2013-December 2019 at a private IVF clinic (n = 2676 patients undergoing 2676 treatments and producing and 8151 blastocysts). m-ER were investigated according to women's reproductive history of LBs: no/≥1, miscarriages: no/1/>1; failed IVF cycles: no/1/2/>2, and implantation failures after previous transfers: no/1/2/>2. Among the 2676 patients included in this study, 440 (16%) had already undergone PGT-A before the study period; the data from these patients were further clustered according to the presence or absence of euploid embryo(s) in their previous cohort of biopsied blastocysts. The clinical outcomes per first single vitrified-warmed euploid blastocyst transfers (n =1580) were investigated according to the number of patients' previous miscarriages and implantation failures. PARTICIPANTS/MATERIALS, SETTING, METHODS: The procedures involved in this study included ICSI, blastocyst culture, trophectoderm biopsy without hatching in Day 3, CCT-based PGT-A without reporting segmental and/or putative mitotic (or mosaic) aneuploidies and single vitrified-warmed euploid blastocyst transfer. For statistical analysis, Mann-Whitney U or Kruskal-Wallis tests, as well as linear regressions and generalised linear models among ranges of maternal age at oocyte retrieval were performed to identify significant differences for continuous variables. Fisher's exact tests and multivariate logistic regression analyses were instead used for categorical variables. MAIN RESULTS AND THE ROLE OF CHANCE: Maternal age at oocyte retrieval was the only variable significantly associated with the m-ER. We defined five clusters (<35 years: 66 ± 31%; 35-37 years: 58 ± 33%; 38-40 years: 43 ± 35%; 40-42 years: 28 ± 34%; and >42 years: 17 ± 31%) and all analyses were conducted among them. The m-ER did not show any association with the number of previous LBs, miscarriages, failed IVF cycles or implantation failures. Among patients who had already undergone PGT-A before the study period, the m-ER did not associate with the absence (or presence) of euploid blastocysts in their former cohort of biopsied embryos. Regarding clinical outcomes of the first single vitrified-warmed euploid blastocyst transfer, the implantation rate was 51%, the miscarriage rate was 14% and the LBR was 44%. This LBR was independent of the number of previous miscarriages, but showed a decreasing trend depending on the number of previous implantation failures, reaching statistical significance when comparing patients with >2 failures and patients with no prior failure (36% versus 47%, P < 0.01; multivariate-OR adjusted for embryo quality and day of full blastocyst development: 0.64, 95% CI 0.48-0.86, P < 0.01). No such differences were shown for previous miscarriage rates. LIMITATIONS, REASONS FOR CAUTION: The sample size for treatments following a former completed PGT-A cycle should be larger in future studies. The data should be confirmed from a multicentre perspective. The analysis should be performed also in non-PGT cycles and/or including patients who did not produce blastocysts, in order to investigate a putative association between women's reproductive history with outcomes other than euploidy and LBRs. WIDER IMPLICATIONS OF THE FINDINGS: These data are critical to counsel infertile couples before, during and after a PGT-A cycle, especially to prevent treatment discontinuation due to previous adverse reproductive events. Beyond the 'maternal age effect', the causes of idiopathic recurrent pregnancy loss (RPL) and RIF are likely to be endometrial receptivity and selectivity issues; transferring euploid blastocysts might reduce the risk of a further miscarriage, but more information beyond euploidy are required to improve the prognosis in case of RIF. STUDY FUNDING/COMPETING INTEREST(S): No funding was received and there are no competing interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Cimadomo D, Capalbo A, Dovere L, et al. Leave the past behind: women's reproductive history shows no association with blastocysts' euploidy and limited association with live birth rates after euploid embryo transfers. Hum Reprod. 2021. PMID: 33608730. doi:10.1093/humrep/deab014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。